532 related articles for article (PubMed ID: 9363045)
1. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
Small GW; Bystritsky A
J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
[TBL] [Abstract][Full Text] [Related]
2. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
[TBL] [Abstract][Full Text] [Related]
3. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
Lydiard RB; Ballenger JC; Rickels K
J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
[TBL] [Abstract][Full Text] [Related]
4. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder.
Ballenger JC; McDonald S; Noyes R; Rickels K; Sussman N; Woods S; Patin J; Singer J
Psychopharmacol Bull; 1991; 27(2):171-9. PubMed ID: 1681563
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
Lemoine P; Touchon J; Billardon M
Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
[TBL] [Abstract][Full Text] [Related]
6. Abecarnil, a new beta-carboline, in the treatment of anxiety disorders.
Aufdembrinke B
Br J Psychiatry Suppl; 1998; (34):55-63. PubMed ID: 9829018
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
8. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder.
Ballenger JC; McDonald S; Noyes R; Rickels K; Woods SW; Patin J; Lydiard B; Garvey M; Cook B; Goodard AW
Adv Biochem Psychopharmacol; 1992; 47():431-47. PubMed ID: 1354920
[No Abstract] [Full Text] [Related]
9. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of bedtime dosing of benzodiazepines: a placebo-controlled comparison of halazepam and clorazepate.
Aden GC; O'Hair DE
Clin Ther; 1980; 3(3):209-18. PubMed ID: 6109568
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder.
Rickels K; DeMartinis N; Aufdembrinke B
J Clin Psychopharmacol; 2000 Feb; 20(1):12-8. PubMed ID: 10653203
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
15. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.
Mercier-Guyon C; Chabannes JP; Saviuc P
Curr Med Res Opin; 2004 Sep; 20(9):1347-55. PubMed ID: 15383182
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of generalized anxiety: new pharmacologic approaches].
Boulenger JP
Encephale; 1995; 21(6):459-66. PubMed ID: 8674471
[TBL] [Abstract][Full Text] [Related]
17. Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder.
De Candia MP; Di Sciascio G; Durbano F; Mencacci C; Rubiera M; Aguglia E; Garavini A; Bersani G; Di Sotto A; Placidi G; Cesana BM
Clin Ther; 2009 Dec; 31(12):2851-9. PubMed ID: 20110024
[TBL] [Abstract][Full Text] [Related]
18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
